Shaping the future
treatment of
immune-mediated
diseases
Attovia™ is advancing a new generation of precision biologics for patients with high unmet need across immune-mediated diseases.
At the core of our strategy is the ATTOBODY™ platform, a powerful, modular protein design platform to create novel complex biologic medicines.
We’re driven by one goal: to change what patients can expect from their treatments and from their futures.
Shaping the future
treatment of
immune-mediated
diseases
Attovia™ is advancing a new generation of precision biologics for patients with high unmet need across immune-mediated diseases.
At the core of our strategy is the ATTOBODY™ platform, a powerful, modular protein design platform to create novel complex biologic medicines.
We’re driven by one goal: to change what patients can expect from their treatments and from their futures.
Leading the way to breakthrough multispecifics
We are a team of veteran drug development leaders passionate about bringing new and improved medicines to patients.
Tao Fu, MBA, M.S.
Chief Executive Officer
Steven Chan
Chief Financial Officer
Hubert Chen, M.D., M.P.H.
Chief Medical Officer
Zaneta Odrowaz, PhD
Chief Business Officer
Petter Veiby
Chief Scientific Officer
Hangjun Zhan, Ph.D.
Chief Technology Officer
Bora Han, Ph.D.
VP, Head of Preclinical Development
Veit Schmelmer, Ph.D.
VP, Project Management & Portfolio Strategy
Tao Fu, MBA, M.S.
Chief Executive Officer
Steven Chan
Chief Financial Officer
Hubert Chen, M.D., M.P.H.
Chief Medical Officer
Zaneta Odrowaz, PhD
Chief Business Officer
Petter Veiby
Chief Scientific Officer
Hangjun Zhan, Ph.D.
Chief Technology Officer
Bora Han, Ph.D.
VP, Head of Preclinical Development
Veit Schmelmer, Ph.D.
VP, Project Management & Portfolio Strategy
Hubert Chen, M.D., M.P.H.
Hangjun Zhan, Ph.D.
